Hemolytic anemia in COVID-19.
Ann Hematol
; 101(9): 1887-1895, 2022 Sep.
Статья
в английский
| MEDLINE | ID: covidwho-2248675
ABSTRACT
COVID-19 is a global pandemic triggered by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 entry point involves the interaction with angiotensin-converting enzyme 2 (ACE2) receptor, CD147, and erythrocyte Band3 protein. Hemolytic anemia has been linked to COVID-19 through induction of autoimmune hemolytic anemia (AIHA) caused by the formation of autoantibodies (auto-Abs) or directly through CD147 or erythrocyte Band3 protein-mediated erythrocyte injury. Here, we aim to provide a comprehensive view of the potential mechanisms contributing to hemolytic anemia during the SARS-CoV-2 infection. Taken together, data discussed here highlight that SARS-CoV-2 infection may lead to hemolytic anemia directly through cytopathic injury or indirectly through induction of auto-Abs. Thus, as SARS-CoV-2-induced hemolytic anemia is increasingly associated with COVID-19, early detection and management of this condition may prevent the poor prognostic outcomes in COVID-19 patients. Moreover, since hemolytic exacerbations may occur upon medicines for COVID-19 treatment and anti-SARS-CoV-2 vaccination, continued monitoring for complications is also required. Given that, intelligent nanosystems offer tools for broad-spectrum testing and early diagnosis of the infection, even at point-of-care sites.
ключевые слова
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
COVID-19
/
COVID-19 Drug Treatment
/
Anemia, Hemolytic
Тип исследования:
Прогностическое исследование
Темы:
Длинный Ковид
/
Вакцина
Пределы темы:
Люди
Язык:
английский
Журнал:
Ann Hematol
Тематика журнала:
Гематология
Год:
2022
Тип:
Статья
Аффилированная страна:
S00277-022-04907-7
Документы, близкие по теме
MEDLINE
...
LILACS
LIS